Prenetics stock price target raised to $14 on strong Q1 results

Cantor Fitzgerald raised its price target on Prenetics (PRE) to $14 from $13, maintaining an Overweight rating after the company reported strong Q1 2025 revenue growth of approximately 170%, driven by its IM8 and Europa business lines. Prenetics, which is up over 31% year-to-date, expects further growth in its IM8 business and has raised its 2025 guidance, while also planning to divest its ACT Genomics business and convert its balance sheet to cryptocurrency. Cantor Fitzgerald views Prenetics as undervalued, trading at 0.6x enterprise value to estimated 2025 revenue, compared to peers at 6.1x, and anticipates strong revenue growth as the company works toward break-even operations.

Analysis

Cantor Fitzgerald has upgraded its price target for Prenetics (NASDAQ:PRE) to $14.00 from $13.00, reiterating an Overweight rating, following robust first-quarter 2025 financial results. The company reported a significant 170% year-over-year increase in revenue from continuing operations, reaching $17.3 million, largely propelled by its IM8 and Europa business lines; notably, the newly launched IM8 business contributed $5.7 million. Prenetics showcased strong operational efficiency with a gross profit margin of 50.3% and anticipates its IM8 segment to expand by approximately 50% in the second quarter. While specific figures were not disclosed, the company has raised its full-year 2025 guidance. Strategically, Prenetics is pursuing the divestiture of its ACT Genomics business and has an unconventional plan to convert its balance sheet to cryptocurrency. Despite a year-to-date stock appreciation of over 31% and an InvestingPro 'GOOD' financial health score, Cantor Fitzgerald highlights that Prenetics trades at a compelling 0.6 times enterprise value to estimated 2025 revenue, a significant discount compared to slower-growing peers averaging 6.1 times. This valuation, coupled with strong revenue growth prospects and a trajectory towards break-even operations, underpins Cantor Fitzgerald's view of the shares as undervalued, further supported by a consensus 'Strong Buy' rating from analysts tracked by InvestingPro, even as InvestingPro's own analysis suggests the stock is fairly valued.

Key Decisions for Investors

• Investors should consider the significant growth reported by Prenetics, particularly from its IM8 business, and the positive outlook reflected in Cantor Fitzgerald's price target increase and Overweight rating, while noting the stock's substantial year-to-date gains.
• The current valuation at 0.6 times enterprise value to estimated 2025 revenue, as highlighted by Cantor Fitzgerald, presents a potential opportunity, especially when compared to peer group multiples, but this should be weighed against InvestingPro's 'fairly valued' assessment.
• Careful monitoring of the execution and implications of strategic initiatives, including the divestment of ACT Genomics and the novel plan to convert the balance sheet to cryptocurrency, is warranted due to their potential impact on the company's risk profile and financial structure.
• Focus on the company's ability to sustain its high revenue growth trajectory and achieve its guidance of moving towards break-even operations as key indicators for future performance.